TG Therapeutics Q2 rev up 8.5% YoY to $141.1mln, raises FY25 BRIUMVI target to $570-$575mln.

• TG Therapeutics Q2 2025 revenue: $141.1 million • BRIUMVI US net revenue: $138.8 million • Raises FY 2025 BRIUMVI US net revenue target: $570-$575 million • Strong uptake and physician confidence in BRIUMVI • Update on 2025 revenue guidance provided • Conference call to be held on August 4, 2025, at 8:30 AM ET

TG Therapeutics (NASDAQ: TGTX) has released its second-quarter (Q2) 2025 financial results, showcasing robust performance and raising its full-year 2025 revenue guidance. The biopharmaceutical company reported total revenue of $141.1 million, with BRIUMVI U.S. net revenue reaching $138.8 million, representing a 91% year-over-year growth and 16% growth over Q1 2025 [2].

The company's flagship product, BRIUMVI, has seen strong uptake and physician confidence, contributing significantly to the revenue growth. TG Therapeutics has updated its full-year 2025 BRIUMVI U.S. net revenue target to approximately $570-$575 million, reflecting the positive market reception and clinical trial advancements [2].

The Q2 2025 financial results also include net income of $28.2 million and a strong cash position of $278.9 million. The company's pipeline is advancing with new clinical trials, including a Phase 3 program for consolidated BRIUMVI dosing and development of a subcutaneous formulation [2].

TG Therapeutics will host a conference call on August 4, 2025, at 8:30 AM ET, to discuss the financial results and provide an update on 2025 revenue guidance. Investors and financial professionals are encouraged to participate to gain further insights into the company's performance and future prospects.

References:
[1] https://www.marketbeat.com/instant-alerts/tg-therapeutics-tgtx-to-release-quarterly-earnings-on-tuesday-2025-07-29/
[2] https://www.stocktitan.net/news/TGTX/tg-therapeutics-reports-second-quarter-2025-financial-results-and-gk27yackstrn.html